Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Aichi Cancer Center · Yokohama City University Medical Center · +14 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
4,111
total citations
- FWCI
- 166.44
- Percentile
- 100%
- References
- 35
Citations per year
Authors
21Topics & keywords
Topics
Keywords
- Medicine
- Gefitinib
- Docetaxel
- Internal medicine
- Clinical endpoint
- Lung cancer
- Oncology
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.